Journal of Clinical Oncology
Articles in this Issue
Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program.
3623 Background: ctDNA positivity is a strong prognostic biomarker for recurrence after curative-intent procedures for CRC...
Multiomic machine learning integration of DNA and RNA features to predict immunotherapy benefit in MSS-CRC and other rare cancers.
2531 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the oncology landscape, yet remain constrained by...
Spatiotemporal evolution of immune evasion: Divergent resistance mechanisms in primary refractory versus new primary cutaneous squamous cell carcinomas during anti-PD1 therapy.
e21553 Background: While anti-PD1 therapy is effective in advanced cutaneous squamous cell carcinoma (cSCC), ~50% of patie...
PSA nadir–stratified outcomes of ARPI doublet and docetaxel triplet therapy in metastatic prostate cancer.
e17096 Background: Therapy intensification has expanded combination strategies in metastatic prostate cancer (mPC) with im...
Incidentally discovered lung cancer in explanted lungs at the time of lung transplantation: Management and outcomes.
e20087 Background: Lung transplantation is an established therapy for end-stage pulmonary disease. Occult lung cancer is i...
Incremental clinical yield of serial large NGS panel liquid biopsies in routine care: Analysis of the STING study.
3046 Background: Plasma ctDNA profiling is increasingly repeated over the disease course to capture tumor evolution and ne...
Prognostic value of <i>ESR1</i> mutation status in patients with metastatic breast cancer receiving second-line therapy: A real-world evidence study.
e13140 Background: ESR1 mutations emerge during endocrine therapy and are associated with endocrine re...
Healthcare utilization and health expenditures among U.S. adults by cancer and atherosclerotic cardiovascular disease status.
e23191 Background: Improvements in cancer prognosis have led to a growing population of cancer survivors who are at increa...
Conditional survival by primary extranodal site in diffuse large B-cell lymphoma: A population-based landmark analysis.
7071 Background: Diffuse large B-cell lymphoma (DLBCL) frequently presents with extranodal involvement. Prior population-b...
Comparative analysis of subcutaneous Isa VRd (ISASOCUT) and intravenous Isa VRd (IMROZ) in transplant-ineligible newly diagnosed multiple myeloma across age groups.
7561 Background: Intravenous (IV) isatuximab (Isa) plus bortezomib, lenalidomide, and dexamethasone (VRd) significantly im...
Clinicopathologic features and survival outcomes of stage IE pulmonary marginal zone lymphoma: A National Cancer Database (NCDB) analysis.
e19076 Background: Pulmonary marginal zone lymphoma (PMZL) is a rare, indolent B-cell neoplasm and the most common form of...
The use of circulating tumor DNA to stratify the risk of recurrence after surgical debulking in epithelial ovarian cancer.
5604 Background: Accurate risk stratification after debulking surgery in ovarian cancer remains challenging. Although surg...
Projected burden of lung cancer and pneumonia among older adults in the United States: A CDC WONDER forecasting analysis, 1999–2035.
e23066 Background: Lung cancer and pneumonia commonly coexist and contribute substantially to mortality in older adults. E...
Evaluation of baseline circulating eMDSCs in patients with advanced non–small cell lung cancer treated with first-line immunotherapy-based treatment.
e20616 Background: Early myeloid-derived suppressor cells (eMDSCs) are implicated in tumor-driven immune dysregulation, bu...
Distinguishing hemoglobin nadir from clinically significant anemia events during curative treatment for early breast cancer: Mapping hemoglobin trajectories.
e23389 Background: Anemia is a frequent complication during treatment for early breast cancer (EBC), yet the temporal rela...
Propensity score–matched analysis of trifluridine-tipiracil plus bevacizumab (FTD/TPI+Bev) vs anti-EGFR re-treatment in pretreated metastatic colorectal cancer (mCRC).
3581 Background: The SUNLIGHT trial established FTD/TPI+Bev as a preferred 3rd-line option for unselected mCRC patients (p...
Longitudinal physical activity patterns and patient-reported cognitive function among patients with lymphoma receiving chemotherapy in a nationwide prospective cohort.
12111 Background: Up to 70% of patients with cancer experience cancer-related cognitive impairment and physical activity (...
A randomized phase III trial of chemo-immunotherapy vs immunotherapy alone for the vulnerable older adult with advanced non–small cell lung cancer: The ACHIEVE study—ECOG-ACRIN EA5221.
TPS8674 Background: Lung cancer disproportionately affects older adults, with 70% of cases diagnosed in patients ≥65 years...
Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.
7513 Background: The phase 3 CEPHEUS study established that DVRd improved overall minimal residual disease (MRD)-negativit...
Development of an oncology generative AI foundation model trained on more than a million longitudinal patient journeys across the United States.
10558 Background: Incidence of cancer diagnoses continues to increase, while the average cost of cancer screening, such as...
Comparative efficacy of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs standard of care in patients with relapsed/refractory multiple myeloma (RRMM).
7568 Background: BVd is approved in the United States as a third-line or later (3L+) option for patients with RRMM based o...
Sharing geriatric and functional status assessment data with older adults who have cancer: Patients’ preferences and utility.
e13761 Background: Geriatric assessments (GA) improve clinical outcomes for older adults undergoing cancer treatment, but...
Large-scale assessment of ChatGPT performance in medical oncology clinical decision-making.
e13664 Background: Large Language Models (LLMs) hold significant promise as a support tool in oncology decision-making. Ho...
Time of day of liver transplant reperfusion as a predictor of disease-free and overall survival in patients with advanced hepatocellular carcinoma.
e16282 Background: Circadian rhythms moderate cancer biology by regulating cell cycle progression, DNA activity, immune su...
Efficacy and circulating protein biomarkers of second-line aflibercept plus FOLFIRI according to prior bevacizumab or cetuximab treatment in advanced colorectal cancer (KCSG CO21-21).
3566 Background: Prospective data evaluating second-line aflibercept plus FOLFIRI according to prior bevacizumab (BEV) or...